Is Progyny (PGNY) Priced At A Premium For Its Earnings?

Simply Wall St.10-30

Progyny has delivered a mixed experience for shareholders over the past few years, and the recent share price level puts a sharper spotlight on what investors are really paying for its earnings. With ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679280152?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice2-card/1789111483077","is_english":true,"pubTime":"2026-10-30 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679280152","market":"nz","top_or_hot":-1,"title":"Is Progyny (PGNY) Priced At A Premium For Its Earnings?","media":"Simply Wall St.","content":"<div>\n<p>Progyny has delivered a mixed experience for shareholders over the past few years, and the recent share price level puts a sharper spotlight on what investors are really paying for its earnings. With ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/is-progyny-pgny-priced-at-a-premium-for-its-earnings\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Progyny (PGNY) Priced At A Premium For Its Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Progyny (PGNY) Priced At A Premium For Its Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-30 00:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/is-progyny-pgny-priced-at-a-premium-for-its-earnings><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Progyny has delivered a mixed experience for shareholders over the past few years, and the recent share price level puts a sharper spotlight on what investors are really paying for its earnings. With ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/is-progyny-pgny-priced-at-a-premium-for-its-earnings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGNY","symbol_name":"Progyny","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/is-progyny-pgny-priced-at-a-premium-for-its-earnings","article_id":"2679280152","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice2-card/1789111483077"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/is-progyny-pgny-priced-at-a-premium-for-its-earnings","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679280152","pubTimestamp":1793291863,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Progyny has delivered a mixed experience for shareholders over the past few years, and the recent share price level puts a sharper spotlight on what investors are really paying for its earnings. With the stock closing at US$27.87, the key issue is how that price lines up with the fertility benefits specialist's ability to generate profit today.\n\nProgyny's share price has fallen 53.8% over the past 5 years, which puts long term holders squarely focused on whether current earnings now justify...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PGNY":"Progyny"},"translate_title":"Progyny (PGNY) 的盈利定价是否溢价？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1.5},"content_text":"Progyny has delivered a mixed experience for shareholders over the past few years, and the recent share price level puts a sharper spotlight on what investors are really paying for its earnings. With the stock closing at US$27.87, the key issue is how that price lines up with the fertility benefits specialist's ability to generate profit today.  Progyny's share price has fallen 53.8% over the past 5 years, which puts long term holders squarely focused on whether current earnings now justify staying invested. The new menopause outcomes study, showing symptom improvement for members using Progyny's connected care model, may support arguments that the business can sustain demand and potentially reinforce its earnings base over time. There is a second opinion on Progyny worth weighing. See what analysts think Progyny's shares could be worth.  The stock's next move may depend on whether Progyny's current earnings are strong enough to support the price investors are being asked to pay today. If you are weighing Progyny against other profit focused opportunities, it can help to see how a wider group of companies with earnings support are priced through the 26 high quality undervalued stocks AdvertisementDoes Progyny Look Fairly Valued on Earnings? The P/E ratio suits Progyny because the business already reports profits that give a concrete earnings base. At a P/E of about 27.2x, the stock trades slightly above the broader healthcare industry average of roughly 25.4x, yet below the peer group near 34.3x. That combination suggests investors are paying a premium to the sector overall but are not assigning the same valuation as they are to some closer comparables. Because the new menopause outcomes study highlights a defined service offering with measurable health results, the market may be giving Progyny credit for an established earnings engine rather than a purely speculative story. The current P/E also sits close to what the tailored fair multiple model would imply for a business with Progyny's mix of margins, growth expectations and risk profile, so the listed valuation does not screen as either clearly overvalued or clearly cheap on this measure. Explore the numbers behind Progyny's P/E valuation. NasdaqGS:PGNY P/E Ratio as at Oct 2026 The Progyny Narrative: What Would Justify Today's Price? Narratives pick up where Progyny's valuation puzzle leaves off by explaining which assumptions about future growth, profitability and earnings power would need to occur for the current share price to appear high or low. Each narrative presents Progyny's implied fair value as a specific, trackable thesis about the business, so you can observe how that view holds up over time on Simply Wall St's Community page. One of the top community narratives on Progyny: 19% undervalued \"The valuation currently reflects that the recent share price decline following lower EBITDA guidance and modestly softer growth expectations is giving limited credit to Progyny's cash generation...\" Discover why this Narrative puts Progyny at 19% undervalued. Progyny's valuation still leaves one powerful angle unresolved Numbers tell only part of Progyny's story. The people setting priorities and the way they are rewarded can strongly influence how that earnings base is treated over time. See who runs Progyny and how they are paid. This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679280152","isCrawlerRequest":true}